Esophagitis

05/01/1980 - "These studies indicate that (1) the acid reflux test correlates most closely with symptoms of GER; (2) THE GE scintiscan is complementary to the UGI in the diagnosis of GER, i.e., the combination increases sensitivity; (3) normal LESP does not necessarily exclude GER; and (4) endoscopy is superior to the UGI in detecting the presence of esophagitis."
04/01/2012 - "At time of follow-up evaluation, use of acid-suppression medication was significantly greater in the group with histologic evidence for esophagitis, compared with patients who had normal histology findings when the study began. "
10/03/2023 - "Among the 51 patients (71.8%) who underwent 24-h pH monitoring, the median acid exposure time decreased from 5.3% to 0.7% (P = 0.003), accompanied by a significant reduction in esophagitis rates (P < 0.001). "
04/01/2001 - "In both the patients with esophagitis and the controls, esophageal acid exposure (15.3% (4.9%-28.2%) versus 2.7% (0.0%-10.8%), P=0.003; 5.9% (0.5%-6.7%) versus 0.0% (0.0%-1.5%), P = 0.01) and events of acid reflux (5 (1-16) versus 2 (0-8), P = 0.02; 12 (3-17) versus 1 (0-4), P = 0.02) were significantly greater during jejunal meal feeding than during saline infusion. "
07/01/1980 - "Patients with esophagitis did not have significantly greater acid exposure than those without esophagitis. "

01/01/2001 - "In patients with moderate or severe esophagitis, proton pump inhibitors are the mainstay of treatment and the most effective in preventing symptoms and esophagitis. "
09/01/1997 - "In these patients with endoscopic evidence of damaged esophageal mucosa, both proton pump inhibitors were highly effective and safe in acute healing of erosive esophagitis and were significantly better than H2 receptor antagonists, healing faster and much more completely, with shorter durations of treatment. "
09/01/2009 - "Although proton pump inhibitors (PPIs) are very effective in the treatment of esophagitis, a significant proportion of patients have persistent symptoms even during high dosing of PPIs. "
07/14/2005 - "Proton pump inhibitors given at the recommended dose are equally effective for healing esophagitis."
01/01/2000 - "However, use of H2-receptor antagonists at higher doses and higher frequency approaches the efficacy of proton pump inhibitors in healing erosive esophagitis. "

09/01/1997 - "This study indicates that omeprazole is highly effective for all grades of esophagitis in the intellectually disabled. "
01/01/2010 - "In conclusion, omeprazole given at a dose ranging from 0.3 to 3.5 mg/kg once daily (median 1 mg/kg once daily) for at least 12 weeks is highly effective in childhood esophagitis."
11/01/1998 - "Omeprazole is highly effective for all grades of esophagitis in intellectually disabled children, without adverse effects. "
07/01/1993 - "We found omeprazole to be highly effective in this group of patients with severe esophagitis refractory to other measures. "
02/01/2001 - "Marked improvement was noted in symptoms of GER and severity of esophagitis while taking omeprazole. "

04/01/2002 - "Esomeprazole is effective in the healing of erosive esophagitis, with a rate of healing at week 8 of 93.7% (p < 0.001). "
01/01/2018 - "Phase II clinical trials showed that, compared with Esomeprazole, the new PPI Ilaparazole is great in terms of efficacy for reflux symptoms relief and curling for esophagitis. "
08/01/2004 - "Evidence-based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis."
07/01/2015 - "Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study."
07/01/2015 - "Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study."

08/01/2009 - "One hundred ninety-five subjects received lansoprazole for <1 to 72 months; most received daily doses of <or=30 mg. Lansoprazole maintained erosive esophagitis remission in 75% of subjects receiving treatment for <or=72 months, with 39 subjects experiencing 50 recurrences. "
03/01/2005 - "Lansoprazole produced a significant reduction from baseline in the median percentage of days with reflux symptoms (91 to 43% in the 64 adolescents with non-erosive disease and 85 to 16% in the 23 adolescents with erosive esophagitis, P < or = 0.001 for each comparison). "
08/01/2009 - "Long-term lansoprazole is effective and well tolerated when used to maintain erosive esophagitis remission for <or=6 years."
03/01/2005 - "Lansoprazole 30 mg once daily for 8 weeks was effective in healing erosive esophagitis. "
05/01/2010 - "Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole."

06/01/1983 - "Both drugs proved significantly effective in inducing symptomatic and endoscopic improvement, but Ranitidine appeared significantly superior in promoting disappearance or improvement of endoscopic esophagitis. "
06/01/1987 - "The esophagitis, as judged by all observers, improved more in the ranitidine group than in the placebo group, but the difference did not reach statistical significance."
04/01/1993 - "We conclude that ranitidine 150 mg or 300 mg administered four times daily is effective for healing erosive esophagitis and relieving its symptoms."
12/01/1989 - "Treatment with ranitidine 150 mg per os twice a day for 12 weeks improved esophagitis in all patients, but the voice improved in only one of the two patients with completely healed esophagitis. "
04/01/1993 - "Two ranitidine dosages were compared for the treatment of erosive esophagitis in a multicenter, double-blind, randomized, parallel-group, placebo-controlled study. "

07/01/2022 - "This technique is also considered effective for the treatment of corrosive esophagitis."
02/20/2023 - "The aim of our study was to determine the incidence and endoscopic grading of corrosive esophagitis in a cohort of children from a developing country. "
04/01/2015 - "We aimed to investigate whether it has protective effect in experimental corrosive esophagitis, in the absence of existing studies into possible links. "
04/01/2015 - "Its effects are studied in various studies but not in corrosive esophagitis. "
11/01/2013 - "The aim of this study was to evaluate the effect of kefir in an experimental corrosive esophagitis model. "

04/01/1997 - "Sucralfate, prokinetic agents, and H2-receptor antagonists promote symptom relief and esophageal healing in mild esophagitis, but are less effective in the treatment of moderate to severe esophagitis. "
09/28/1987 - "Endoscopy showed improvement in 53 percent of patients and healing of esophagitis in 31 percent after sucralfate treatment. "
08/01/1987 - "Endoscopy showed improvement of esophagitis in 53% and healing in 31% of patients after sucralfate treatment. "
03/01/1997 - "Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis."
03/01/1997 - "There was no substantial benefit from the sucralfate in terms of esophagitis scores. "

11/01/2000 - "Pantoprazole was safe and effective for healing erosive esophagitis and provided rapid symptomatic relief. "
10/01/2013 - "Pantoprazole is effective in relieving upper and lower gastro-intestinal symptoms overlapping with erosive esophagitis, and provides sustained improvement in HRQoL post-treatment. "
09/01/2010 - "Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis."
02/01/2017 - "The results revealed that treatments with pantoprazole and flower extracts significantly inhibited the gastric secretion, total acidity and esophagitis index. "
06/01/2008 - "It is safe to give pantoprazole intravenously and continuously for treatment of severe erosive esophagitis."

08/01/2019 - "Subgroup analysis indicated that vonoprazan is more effective than most PPIs for patients with severe erosive esophagitis."
12/01/2022 - "Vonoprazan is superior to PPI in first-line H. pylori eradication and erosive esophagitis but non-inferior in other gastric acid-related diseases. "
01/01/2021 - "Subgroup analysis indicates that vonoprazan is more effective than PPIs for patients with severe erosive esophagitis. "
01/01/2021 - "The study aimed to investigate the efficacy of vonoprazan 10 mg compared with 20 mg in patients with erosive esophagitis. "
01/01/2021 - "Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study."

01/01/2013 - "The remission rate was significantly lower in the patients with more severe erosive esophagitis based on the LA grade before PPI therapy. "
04/01/2004 - "Following initial treatment, on-demand therapy may be effective in some patients with NERD or mild (GI) erosive esophagitis. "
01/01/2013 - "This study revealed that approximately 40% of the patients did not achieve remission of erosive esophagitis following PPI therapy for a mean of 1.1 years. "
03/01/1992 - "Thus, there is now a medical "gold standard" against which surgical therapy for uncomplicated esophagitis must be judged and it is essential that all future studies be conducted with clearly defined criteria for the assessment of the symptoms and endoscopic signs of esophagitis and its complications. "
12/01/2014 - "Five patients demonstrated improved esophagitis, three were able to discontinue PPI therapy, and three were able to reduce their PPI dosage following surgery. "

12/01/1996 - "More than 90% of the patients in this series were symptomatically improved, and 92% of those studied endoscopically had healed esophagitis and intact fundoplication. "
01/01/2011 - "The above results show efficacy of fundoplication as a method of esophagitis prevention. "
01/01/2022 - "Preoperative and postoperative Eckardt score, postoperative DeMeester score (24- or 48-hour pH studies), and endoscopic evidence of esophagitis were collected and analyzed to determine the effectiveness and safety of the fundoplication. "
07/01/1999 - "The aim of this study was to compare the utilization of health care resources and long term outcome of erosive esophagitis in patients treated with and without open Nissen fundoplication. "
02/01/1997 - "This study was performed to determine whether the degree of esophagitis preoperatively influences the clinical outcome after laparoscopic Nissen fundoplication. "

01/01/1995 - "Indeed, increasing dose intensity of radiotherapy, eg, twice-daily treatment, increases esophagitis, perhaps reduces local failure, but has not improved overall survival. "
01/01/2023 - "Of the 33 participants included in the study, 30, including three participants (10%) with esophagitis of grade 3 or above and two participants (6.7%) with advanced radiation nerve injury, successfully underwent postoperative high-dose radiotherapy. "
07/01/2022 - "The purpose of the current study was to evaluate the correlation between the dose-volume parameters and the esophagitis in patients who received radiotherapy in the cervicothoracic region. "
04/01/1999 - "In the three phase II trials, esophagitis was the main toxicity, with incidences ranging from 17% to 26% using Radiation Therapy Oncology Group criteria. "
07/23/2023 - "Using multiple regression analysis, mean esophageal dose ≥13 Gy (OR=3.33, 95% CI: 1.23-9.01, P=0.018) and the overlapping volume between planning target volume (PTV) and esophageal ≥8 cm(3)(OR=3.99, 95% CI: 1.24-12.79, P=0.020) were identified as the independent risk factors associated with acute esophagitis grade ≥2 in the hypofractionated radiotherapy group. "

09/01/2005 - "The most common locoregional grade 3/4 toxicity during and after TRT was esophagitis, which was more pronounced with the administration of concurrent chemoradiotherapy on study arms 2 and 3 (19% and 28%, respectively). "
01/01/2016 - "The parameters including Dmax, Dmean, V20, V30, V50, and V55 may be valuable in predicting the occurrence of radiation esophagitis in patients receiving concurrent chemoradiotherapy. "
10/01/2014 - "Eighteen patients (37%) did not develop radiation-induced esophagitis associated with their course of chemoradiotherapy. "
06/01/2014 - "Although its incidence is extremely rare, acute phlegmonous esophagitis may occur as a life-threatening complication of chemoradiotherapy."
06/01/2014 - "Acute phlegmonous esophagitis as a rare but threatening complication of chemoradiotherapy: report of a case."

12/01/2023 - "PEG also improved the synchronous chemotherapy completion rate and reduced the occurrence of at least grade 2 radiation esophagitis. "
04/01/2012 - "Multivariate statistical model building with cross-validation suggests that a two-variable logistic model based on mean dose and the use of concurrent chemotherapy robustly predicts acute esophagitis risk in combined-data WUSTL and RTOG 93-11 trial datasets."
01/01/2023 - "However, the chemotherapy regimen, age, and smoking status did not affect esophagitis development."
01/01/2023 - "Our results showed that Dmean, V10, and V20 were the significant factors for the development of esophagitis, whereas esophagitis was not significantly associated with the chemotherapy regimen, age, and smoking status. "
01/01/2023 - "The following factors were examined regarding their correlation with grade 1 or worse esophagitis by univariate and multivariate analyses: age, chemotherapy, smoking history, maximum dose (Dmax), mean dose (Dmean), esophagus volume receiving 10 Gy (V10), esophagus volume receiving 20 Gy (V20), and length of esophagus in the treatment field. "